ABT logo

Abbott Laboratories Stock Price

NYSE:ABT Community·US$154.0b Market Cap
  • 2 Narratives written by author
  • 1 Comments on narratives written by author
  • 300 Fair Values set on narratives written by author

ABT Share Price Performance

US$88.41
-44.85 (-33.66%)
US$116.54
Fair Value
US$88.41
-44.85 (-33.66%)
24.1% undervalued intrinsic discount
US$116.54
Fair Value
Price US$88.41
AnalystConsensusTarget US$116.54
NateF US$113.88

ABT Community Narratives

·
Fair Value US$116.54 24.1% undervalued intrinsic discount

ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead

4users have liked this narrative
1users have commented on this narrative
157users have followed this narrative
Fair Value
·
Fair Value US$113.88 22.4% undervalued intrinsic discount

ABT Market Outlook

2users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
US$113.88
22.4% undervalued intrinsic discount
Fair Value
Revenue
6.57% p.a.
Profit Margin
13.94%
Future PE
34.37x
Price in 2030
US$158.84

Trending Discussion

Updated Narratives

ABT logo

ABT Market Outlook

Fair Value: US$113.88 22.4% undervalued intrinsic discount
6 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ABT logo

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing

Fair Value: US$116.54 24.1% undervalued intrinsic discount
157 users have set this as their fair value
1 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued established dividend payer.

2 Risks
4 Rewards

Abbott Laboratories Key Details

US$45.1b

Revenue

US$19.6b

Cost of Revenue

US$25.5b

Gross Profit

US$19.3b

Other Expenses

US$6.3b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
3.59
56.50%
13.85%
64.8%
View Full Analysis

About ABT

Founded
1888
Employees
115000
CEO
Robert Ford
WebsiteView website
www.abbott.com

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Recent ABT News & Updates

Analysis Article 3h

Abbott Laboratories (ABT) Stock Could Be 24% Below Fair Value Before Earnings

Dividend affirmation and earnings catalyst put Abbott Laboratories stock in focus Recent commentary on Abbott Laboratories (ABT) has centered on upcoming earnings and Citi highlighting the value of its diversified healthcare businesses, setting the stage for closer attention to the stock. The reaffirmed quarterly dividend and the approaching July 16 earnings report give investors timely reference points as they weigh Abbott Laboratories stock, its current business mix, and expectations around...
Narrative Update Jun 16

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing

Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower from about $117.29 to $116.54, reflecting a series of reduced Street price targets that cite utilization and inflation headwinds, while still applying a modestly lower discount rate and a slightly softer future P/E assumption. Analyst Commentary Recent Street research on Abbott Laboratories points to a more cautious tone, with many price targets cut and utilization and inflation flagged as key issues.

Recent updates

No updates